Summary
Amgen Inc. reported revenues of $5.87 billion for the third quarter of 2019, a decrease of 3% year-over-year, reflecting ongoing pressures from biosimilar competition, particularly impacting Neulasta® and Sensipar®/Mimpara® sales. Despite the top-line decline, the company demonstrated effective cost management, with operating expenses remaining relatively flat for the quarter. Diluted Earnings Per Share (EPS) saw a slight increase to $3.57, up 3% year-over-year, signaling operational efficiency and a strong focus on profitability. The company continued its robust capital return program, repurchasing $5.4 billion in common stock during the first six months of 2019 and increasing its authorized repurchase amount, demonstrating confidence in its future cash flows and commitment to shareholder value. The balance sheet remains solid, with total assets of $59.37 billion. While cash and cash equivalents decreased to $5.53 billion from $6.95 billion at year-end 2018, the company maintains substantial liquidity through marketable securities. Amgen is actively managing its debt, reducing long-term debt to $27.8 billion. The company's legal and regulatory landscape remains active, with ongoing patent litigations and potential impacts from pricing and reimbursement policies, which investors should monitor closely.
Financial Highlights
54 data points| Revenue | $5.87B |
| Cost of Revenue | $1.01B |
| Gross Profit | $4.56B |
| SG&A Expenses | $1.26B |
| Operating Expenses | $3.19B |
| Operating Income | $2.68B |
| Interest Expense | $332.00M |
| Net Income | $2.18B |
| EPS (Basic) | $3.59 |
| EPS (Diluted) | $3.57 |
| Shares Outstanding (Basic) | 607.00M |
| Shares Outstanding (Diluted) | 610.00M |
Key Highlights
- 1Total revenues declined by 3% year-over-year to $5.87 billion for the quarter, primarily impacted by decreased sales of Neulasta® (-25%) and Sensipar®/Mimpara® (-71%), largely due to biosimilar competition and generic entries.
- 2Diluted Earnings Per Share (EPS) increased by 3% to $3.57 for the quarter, indicating effective cost control and operational efficiency despite lower revenues.
- 3Operating expenses were well-managed, showing a slight decrease of 1% for the quarter, with significant investment in Research and Development (+6%) for oncology programs.
- 4The company continues a strong commitment to returning capital to shareholders, repurchasing $5.4 billion of common stock in the first six months of 2019 and announcing an additional $5.0 billion authorization.
- 5Cash and cash equivalents decreased to $5.53 billion, but total cash, cash equivalents, and marketable securities remain substantial at $21.76 billion, providing ample liquidity.
- 6Long-term debt was reduced to $27.8 billion from $29.5 billion at year-end 2018, demonstrating effective balance sheet management.
- 7The company is actively engaged in various legal and patent litigations, particularly concerning biosimilars and generic competition for key products, which represent ongoing risks and opportunities.